Hikal beaten down after poor Q1

By Research Desk
about 10 years ago

Hikal, jointly promoted by Hiremath and  Kalyani group, is amongst the first companies to offer customized, cost effective and sustainable solutions from R&D to Commercial Manufacturing. It is one of the very few global and only Indian company to provide APIs for both Pharmaceuticals and Agrochemicals.  About 70% of company’s earnings is coming from exports and having strong marketing tie-ups with multinationals includes Bayer, Syngenta, Degussa and Pfizer. And this is what affected the performance of the company is Q1FY16 – adverse currency fluctuations and flat demand.

Net sales for the quarter was flat at Rs.191 crore and then it went to suffer a forex loss of Rs.6.12 crore and that impacted the net profit – it came in at Rs.2 crore v/s Rs.6 crore in Q1FY15.

The stock price has naturally taking a beating and it is down over 8% at Rs.127 levels, with an intra day low at Rs.125. Its 52-week low is at Rs.101.87.